Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2015 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: Robohogs who wrote (228)	1/10/2015 7:30:39 AM
From: tom pope	Read Replies (1) \| Respond to of 407

SEPRACOR (one of Peter's favorites). CHIRON and MILLENIUM. The other two ring a bell, but a faint one.

To: Robohogs who wrote (228)	1/10/2015 11:51:53 AM
From: Jack Hartmann	Respond to of 407

MLNM was Millenium Pharma.

To: Robohogs who wrote (228)	1/10/2015 12:38:31 PM
From: scaram(o)uche	Respond to of 407

Remicade, PCR, IL-2, Lunesta (ooops), Velcade, others. The only loser there that I see, science-wise? I don't remember anything useful from CORR, but it was munched, ironically, by MLNM. So the only loser on the list from an investment stand? And I might be wrong about even that..... SEPR. CHIR gulped by Novartis. CNTO is JNJ. MLNM a big part of Takeda. In general, the assumption that most public biotechs fail? Wrong. edit: As you'll probably remember, in-house MLNM should be defined as one big disappointment, "science-wise", from beginning to end. I was a fan. Ugh.